Apligraf denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for apligraf are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Apligraf as Duplicate Therapy

Cigna's duplicate-therapy denial for Apligraf (a bilayered living cell-based wound therapy) arises when the claims system or a clinical reviewer determines that another wound-care treatment billed at or around the same time overlaps with Apligraf's function. Common scenarios include concurrent billing of a different bioengineered or cellular tissue-based product, or the simultaneous use of advanced moist wound therapy that Cigna's policy defines as serving the same clinical purpose. This denial category is frequently a documentation and coding issue rather than an outright clinical disagreement.

## Why This Denial Is Appealable

Apligraf is a distinct product — a bilayered construct containing living cells — that operates through a different mechanism than standard wound dressings, collagen matrices, or most other advanced therapies. If the concurrent treatment serves a different clinical function (e.g., infection management, mechanical offloading, or debridement), the care is complementary, not duplicative. The appeal requires the treating clinician to explain, in chart terms, why each component of the wound-care regimen addresses a distinct clinical need.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): Submit within the timeframe stated on Cigna's denial letter.
• External review: Available through an accredited IRO after final internal denial, generally within four months of that decision.
• Expedited review: Request if wound progression poses an imminent risk of limb-threatening complication or hospitalization.

## Concrete Appeal Steps and Timeline

1. Obtain Cigna's denial letter and its published coverage policy for Apligraf and for the concurrently billed treatment. 2. Identify which treatment Cigna is calling duplicative and why. 3. Have the treating wound-care specialist write a letter explaining the distinct clinical role of each treatment in the patient's care plan. 4. Review the billing codes submitted; confirm each code accurately reflects a separate, non-overlapping service. 5. Submit the internal appeal with the prescriber letter, wound-care visit notes, and billing documentation. 6. If denied internally, file for external IRO review at once.

## Documentation to Gather

• Wound-care visit notes: Detailed records describing the wound status, the specific goal of each treatment modality, and the clinical rationale for using them concurrently.
• Product differentiation: Written explanation from the treating clinician describing how Apligraf's mechanism differs from the other billed treatment.
• Billing and coding documentation: Confirmation that each service was coded correctly and that no inadvertent overlap was introduced by the coding.
• Cigna coverage policies: Both the Apligraf policy and the policy for the concurrent treatment, to understand exactly how Cigna defines duplication.
• Wound-progress records: Photographs, wound measurements, and any prior treatment history showing the rationale for the multi-modality approach.

## Criteria-Mapping Structure

Create a table with three columns: (1) Cigna's definition of duplicate therapy from its policy; (2) the clinical function of Apligraf as documented in the chart; and (3) the clinical function of the concurrent treatment. Show explicitly where the two functions differ. This makes it structurally clear that the treatments are complementary, not redundant.